Persica 002 Phase 1b PP353 vs Placebo in the Treatment of Low Back Pain

Inclusion Criteria: * Aged between 18 and 70 years, inclusive. * Chronic low back pain in the area associated with vertebral body endplate bone oedema (Modic 1) or vertebral body endplate bone oedema and fat (Modic 1 and 2) at a single lumbar level. * Average LBP NRS score at screening and at Day 1 pre-randomisation ≥ 4 on chronic pain medication and ≥ 6 if not on chronic pain medication; it should be higher than the leg pain NRS score * RMDQ-23 score ≥ 9 at screening and at Day 1 pre-randomisation. * Current episode of chronic low back pain has lasted for ≥ 6 months at the time of randomisation. * Bodyweight of ≥ 50 kg and ≤ 120 kg. * Failure of standard of care therapies used by their treating physician Exclusion Criteria: * Any vertebra with Modic 2 only lesions which: 1. in the opinion of the investigator, after deep palpation of the vertebral spine, is contributing to the low back pain and/or 2. are present within 2 vertebrae from the target lumbar disc. * The target lumbar disc has lost more than half its original anticipated height at the centre or it is \< 5mm in height over the central 15 mm portion * A clear alternative cause for back pain * Gross facet joint degeneration or cases where the investigator believes the primary pain generator to be the facet joints * Interventional back procedure in the 6 months prior to screening or major surgery in the 12 weeks prior to screening * History of alcohol abuse or drugs of abuse in the past 2 years * Any other significant illness * Previously been treated with antimicrobial agents for their low back pain or previously received any antimicrobial intradiscal injection.